The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The Generation and Application of Patient-Derived Xenograft Model for Cancer Research
Open accessAbstract
Establishing an appropriate preclinical model is crucial for translational cancer research. The most common way that has been adopted by far is grafting cancer cell lines, derived from patients. Although this xenograft model is easy to generate, but has several limitations because this cancer model could not represent the unique features of each cancer patient sufficiently. Moreover, accumulating evidences demonstrate cancer is a highly heterogeneous disease so that a tumor is comprised of cancer cells with diverse characteristics. In attempt to avoid these discrepancies between xenograft model and patients' tumor, a patient-derived xenograft (PDX) model has been actively generated and applied. The PDX model can be developed by the implantation of cancerous tissue from a patient's tumor into an immune-deficient mouse directly, thereby it preserves both cell-cell interactions and tumor microenvironment. In addition, the PDX model has shown advantages as a preclinical model in drug screening, biomarker development and co-clinical trial. In this review, we will summarize the methodology and applications of PDX in detail, and cover critical issues for the development of this model for preclinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Global Cancer Incidence and Mortality Rates and Trends—An Update
Torre, L. A., Siegel, R. L., Ward, E. M., & Jemal, A. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0578 · Cited by 3,692
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,728
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain
Cao, X., Shores, E. W., Hu-Li, J., Anver, M. R., Kelsail, B. L., Russell, S. M., Drago, J., Noguchi, M., Grinberg, A., Bloom, E. T., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90047-0 · Cited by 1,038
DeRose, Y. S., Wang, G., Lin, Y.-C., Bernard, P. S., Buys, S. S., Ebbert, M. T. W., Factor, R., Matsen, C., Milash, B. A., Nelson, E., et al. (2011) · Nature Medicine · doi:10.1038/nm.2454 · Cited by 1,002
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 2×
“In addition, the response rate of epidermal growth factor receptor inhibitor cetuximab in PDX model was exactly identical with the results from clinic [18].”
MethodResultModelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Siolas, D., & Hannon, G. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1069 · Cited by 669
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
High drug attrition rates—where are we going wrong?
Hutchinson, L., & Kirk, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.34 · Cited by 517
Establishment of human tumor xenografts in immunodeficient mice
Morton, C. L., & Houghton, P. J. (2007) · Nature Protocols · doi:10.1038/nprot.2007.25 · Cited by 489
Mouse xenograft models vs GEM models for human cancer therapeutics
Richmond, A., & Su, Y. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000976 · Cited by 467
Daniel, V. C., Marchionni, L., Hierman, J. S., Rhodes, J. T., Devereux, W. L., Rudin, C. M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4210 · Cited by 467
A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays
Marangoni, E., Vincent-Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Cremoux, P., de Plater, L., Guyader, C., De Pinieux, G., Judde, J.-G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0078 · Cited by 422
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goéré, D., Mariani, P., Landron, S., Bigot, L., Nemati, F., Dartigues, P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0372 · Cited by 360
Kerbel, R. S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.213 · Cited by 326
SCID Mouse Models of Human Stem Cell Engraftment
Greiner, D. L., Hesselton, R. A., & Shultz, L. D. (1998) · STEM CELLS · doi:10.1002/stem.160166 · Cited by 323
Current status and perspectives of patient-derived xenograft models in cancer research
Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L., & Li, P. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0470-7 · Cited by 295
One mouse, one patient paradigm: New avatars of personalized cancer therapy
Malaney, P., Nicosia, S. V., & Davé, V. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.010 · Cited by 289
Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M., & Merk, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0138 · Cited by 286
Garrido-Laguna, I., Uson, M., Rajeshkumar, N. V., Tan, A. C., de Oliveira, E., Karikari, C., Villaroel, M. C., Salomon, A., Taylor, G., Sharma, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0341 · Cited by 247
Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review
Jin, K., Teng, L., Shen, Y., He, K., Xu, Z., & Li, G. (2010) · Clinical and Translational Oncology · doi:10.1007/s12094-010-0540-6 · Cited by 217
Clinical Approval Success Rates for Investigational Cancer Drugs
DiMasi, J. A., Reichert, J. M., Feldman, L., & Malins, A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.117 · Cited by 203
A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
Sivanand, S., Peña-Llopis, S., Zhao, H., Kucejova, B., Spence, P., Pavia-Jimenez, A., Yamasaki, T., McBride, D. J., Gillen, J., Wolff, N. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003643 · Cited by 193
Molecular profiling of patient-derived breast cancer xenografts
Reyal, F., Guyader, C., Decraene, C., Lucchesi, C., Auger, N., Assayag, F., De Plater, L., Gentien, D., Poupon, M.-F., Cottu, P., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3095 · Cited by 192
Migliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2683 · Cited by 191
Williams, S. A., Anderson, W. C., Santaguida, M. T., & Dylla, S. J. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.92 · Cited by 186
Némati, F., Sastre-Garau, X., Laurent, C., Couturier, J., Mariani, P., Desjardins, L., Piperno-Neumann, S., Lantz, O., Asselain, B., Plancher, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3066 · Cited by 165
Keysar, S. B., Astling, D. P., Anderson, R. T., Vogler, B. W., Bowles, D. W., Morton, J. J., Paylor, J. J., Glogowska, M. J., Le, P. N., Eagles-Soukup, J. R., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.03.004 · Cited by 160
Sebastiani, V., Ricci, F., Rubio-Viquiera, B., Kulesza, P., Yeo, C. J., Hidalgo, M., Klein, A., Laheru, D., & Iacobuzio-Donahue, C. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2655 · Cited by 160
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts
Cho, S., Kang, W., Han, J. Y., Min, S., Kang, J., Lee, A., Kwon, J. Y., Lee, C., & Park, H. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2350 · Cited by 160
Anoikis: Roadblock to Cell Transplantation?
Zvibel, I., Smets, F., & Soriano, H. (2002) · Cell Transplantation · doi:10.3727/000000002783985404 · Cited by 158
Use of nude mouse xenograft models in prostate cancer research
van Weerden, W. M., & Romijn, J. C. (2000) · The Prostate · Cited by 141
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 133
The APL Paradigm and the “Co-Clinical Trial” Project
Nardella, C., Lunardi, A., Patnaik, A., Cantley, L. C., & Pandolfi, P. P. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0061 · Cited by 130
Jiménez-Valerio, G., Martínez‐Lozano, M., Bassani, N., Vidal, A., Ochoa-de-Olza, M., Suárez, C., del Muro, X. G., Carles, J., Viñals, F., Graupera, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.015 · Cited by 120
Choi, Y. Y., Lee, J. E., Kim, H., Sim, M. H., Kim, K.-K., Lee, G., Kim, H., An, J. Y., Hyung, W. J., Kim, C. B., et al. (2016) · Scientific Reports · doi:10.1038/srep22172 · Cited by 115
Kimple, R. J., Harari, P. M., Torres, A. D., Yang, R., Soriano, B. J., Yu, M., Armstrong, E. A., Blitzer, G. C., Smith, M. A., Lorenz, L. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2746 · Cited by 110
Cutz, J., Guan, J., Bayani, J., Yoshimoto, M., Xue, H., Sutcliffe, M., English, J. C., Flint, J., LeRiche, J., Yee, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0252 · Cited by 108
Witkiewicz, A. K., Balaji, U., Eslinger, C. R., McMillan, E. A., Conway, W. C., Posner, B. A., Mills, G. B., O'Reilly, E. M., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.023 · Cited by 94
Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer
Heid, I., Steiger, K., Trajkovic‐Arsic, M., Settles, M., Eßwein, M. R., Erkan, M., Kleeff, J. H., Jäger, C., Friess, H., Haller, B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2432 · Cited by 94
Reyes, G., Villanueva, A., García, C., Sancho, F. J., Piulats, J. M., Lluı́s, F., & Capellá, G. (1996) · PubMed · Cited by 90
Owonikoko, T. K., Zhang, G., Kim, H. S., Stinson, R., Bechara, R. I., Zhang, C., Chen, Z., Saba, N. F., Pakkala, S., Pillai, R. N., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0861-5 · Cited by 89
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
Garrido‐Laguna, I., Tan, A. C., Uson, M. L., Angenendt, M., W, W., Villaroel, M. C., Zhao, M., Rajeshkumar, N. V., Jimeno, A., Donehower, R. C., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605819 · Cited by 80
Aytés, À., Molleví, D. G., Martínez‐Iniesta, M., Nadal, M., Vidal, A., Morales, A., Salazar, R., Capellá, G., & Villanueva, A. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20843 · Cited by 61
Jung, J., Lee, C. H., Seol, H. S., Choi, Y. S., Kim, E., Lee, E. J., Rhee, J., Singh, S. R., Jun, E. S., Han, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11530 · Cited by 60
Self-citationOvarian and cervical cancer patient derived xenografts: The past, present, and future
Boone, J. D., Dobbin, Z. C., Straughn, J. M., & Buchsbaum, D. J. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.022 · Cited by 56
Patient-derived tumour xenografts as models for breast cancer drug development
Marangoni, E., & Poupon, M. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000133 · Cited by 52
Gonçalvès, A., Bertucci, F., Guillé, A., Garnier, S., Adélaı̈de, J., Carbuccia, N., Cabaud, O., Finetti, P., Brunelle, S., Piana, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12714 · Cited by 43
Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts
Lipner, M. B., Marayati, R., Deng, Y., Wang, X., Raftery, L., O’Neil, B. H., & Yeh, J. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147113 · Cited by 35
Assessment of celecoxib pharmacodynamics in pancreatic cancer
Jimeno, A., Amador, M. L., Kulesza, P., Wang, X., Rubio‐Viqueira, B., Zhang, X., Chan, A., Wheelhouse, J., Kuramochi, H., Tanaka, K., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0565 · Cited by 33
Calles, A., Rubio‐Viqueira, B., & Hidalgo, M. M. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1426s61 · Cited by 32
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer
Erriquez, J., Olivero, M., Mittica, G., Scalzo, M. S., Vaira, M., Simone, M. D., Ponzone, R., Katsaros, D., Aglietta, M., Calogero, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8325 · Cited by 16
Fine-Tuning Patient-Derived Xenograft Models for Precision Medicine Approaches in Leukemia
Francis, O. L., Milford, T.-A. M., Beldiman, C., & Payne, K. J. (2016) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000076 · Cited by 13
Cited by
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019) · Genes & Development · doi:10.1101/gad.324301.119 · Cited by 514
Patient-derived xenograft (PDX) models, applications and challenges in cancer research
Abdolahi, S., Ghazvinian, Z., Muhammadnejad, S., Saleh, M., Asadzadeh Aghdaei, H., & Baghaei, K. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03405-8 · Cited by 326
Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Shi, R., Radulovich, N., Ng, C., Liu, N., Notsuda, H., Cabanero, M., Martins-Filho, S. N., Raghavan, V., Li, Q., Mer, A. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1376 · Cited by 316
Molecular biomarkers in acute myeloid leukemia
Prada-Arismendy, J., Arroyave, J. C., & Röthlisberger, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 304
Metadata
- Authors
- Jung, J., Seol, H. S., & Chang, S.
- Venue
- Cancer Research and Treatment
- Publisher
- Korean Cancer Association
- Published
- 2018-01-15
- Volume
- 50
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1598-2998 (ISSN-L)
- 2005-9256
- OpenAlex
- W2754871120
- Cited by
- 310
- References
- 57
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.